

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE FINANCIAL PERIOD ENDED 31 DECEMBER 2022⁽¹⁾

		INDIVIDUAI	L QUARTER	CUMULATI	CUMULATIVE PERIOD		
	Note	UNAUDITED CURRENT QUARTER ENDED 31 DEC 2022 RM'000	UNAUDITED COMPARATIVE QUARTER ENDED 31 DEC 2021 RM'000	UNAUDITED CUMULATIVE PERIOD TO DATE ENDED 31 DEC 2022 RM'000	UNAUDITED CUMULATIVE PRECEDING PERIOD TO DATE ENDED 31 DEC 2021 RM'000		
Revenue	A9	17,114	-	102,476	-		
Cost of sales		(15,628)	-	(87,541)	-		
Gross profit		1,486		14,935			
Other income		111	-	2,280	-		
Administrative expenses		(2,259)	-	(17,357)	-		
Selling and distribution expenses		(354)	-	(2,183)	-		
Other expenses		(24,431)	-	(25,501)	-		
Net gain on impairment of financial assets		3,719	-	6,731	-		
Share of loss of an associate		(2)	-	(47)	-		
Loss from operations		(21,730)		(21,142)			
Finance costs		(118)	-	(407)	-		
Loss before taxation ("LBT")		(21,848)		(21,549)			
Tax expense	B4	223	-	956	-		
Loss after taxation ("LAT")		(21,625)		(20,593)			
Other comprehensive income		-	-	-	-		
Total comprehensive expense for the financial period		(21,625)		(20,593)			
Total comprehensive expense for the financial period attributable to:- Owners of the Company Non-controlling interests		(21,625) (21,625)		(20,488) (105) (20,593)	- 		
Loss per share (sen)							
- Basic ⁽²⁾	B11	(2.23)		(2.21)			

Notes:-

- (1) The basis of preparation of the Unaudited Condensed Consolidated Statements of Profit or loss and Other Comprehensive Income is detailed in Note A1 and should be read in conjunction with the audited financial statements for the financial period ended ("FPE") 30 September 2021 and the accompanying explanatory notes attached to this interim financial report.
- (2) Basic loss per share is calculated based on the weighted average number of ordinary shares in issue.
- (3) The financial year end of the Company and the Group has changed from 30 September to 31 December as announced to Bursa Malaysia Securities Berhad on 22 April 2022. As such, there are no comparative figures available for the corresponding periods in the preceding year.



UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION AS AT 31 DECEMBER 2022 ⁽¹⁾

	Note	UNAUDITED AS AT 31 DEC 2022 RM'000	AUDITED AS AT 30 SEP 2021 RM'000
ASSETS			
Non-current Assets			
Property, plant and equipment		63,939	40,267
Right-of-use assets		3,121	3,061
Investment in quoted shares		24,704	-
		91,764	43,328
Current Assets			
Inventories		10,413	15,045
Trade receivables		7,148	9,867
Other receivables, deposits and prepayments		9,607	2,395
Amount owing by an associate		319	366
Amount owing by a related party		228	228
Current tax assets		4,153	2,322
Fixed deposits with licensed banks		12,000	15,000
Cash and bank balances		14,708	65,662
		58,576	110,885
TOTAL ASSETS		150,340	154,213
EQUITY AND LIABILITIES			
Equity			
Share capital		193,763	179,167
Merger deficit		(29,580)	(29,580)
Accumulated losses		(34,190)	(13,702)
Equity attributable to owners of the Company		129,993	135,885
Non-controlling interests		(667)	(562)
TOTAL EQUITY		129,326	135,323
Non-current Liabilities			
Lease liabilities	B8	1,214	1,471
Term loans	B8	6,734	4,889
	50	7,948	6,360
Current Liabilities			
Trade payables		1,726	4,572
Other payables and accruals		8,369	6,085
Bankers' acceptance	B8	1,368	238
Lease liabilities	B8	1,201	1,213
Term loans	B8	402	422
		13,066	12,530
TOTAL LIABILITIES		21,014	18,890
TOTAL EQUITY AND LIABILITIES		150,340	154,213
Net asset per share (RM) ⁽²⁾		0.13	0.18

Notes:-

- (1) The basis of preparation of the Unaudited Condensed Consolidated Statements of Financial Position is detailed in Note A1 and should be read in conjunction with the audited financial statements for the FPE 30 September 2021 and the accompanying explanatory notes attached to this interim financial report.
- (2) Net asset per share is calculated based on the number of ordinary shares in issue of 971,600,600 shares as at 31 December 2022 and 773,110,600 shares as at 30 September 2021.



UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY FOR THE FINANCIAL PERIOD ENDED 31 DECEMBER 2022⁽¹⁾

	<non-distri Share Capital RM'000</non-distri 	butable> Merger Deficit RM'000	Accumulated Losses RM'000	Total Attributable to Owners of Company RM'000	Non-controlling Interests RM'000	Total Equity RM'000
Balance at 1 October 2021	179,167	(29,580)	(13,702)	135,885	(562)	135,323
Transaction with owners Ordinary shares issued pursuant to:						
- ESOS	2,922	-	-	2,922	-	2,922
- Transfer from ESOS Reserve upon expiration of ESOS	416	-	-	416	-	416
- Private placements	11,258	-	-	11,258	-	11,258
	14,596	-	-	14,596	-	14,596
Loss and other comprehensive expense for the financial period	-	-	(20,488)	(20,488)	(105)	(20,593)
Balance at 31 December 2022	193,763	(29,580)	(34,190)	129,993	(667)	129,326

Note:-

(1) The basis of preparation of the Unaudited Condensed Consolidated Statements of Changes in Equity is detailed in Note A1 and should be read in conjunction with the audited financial statements for the FPE 30 September 2021 and the accompanying explanatory notes attached to this interim financial report.

(2) The financial year end of the Company and the Group has changed from 30 September to 31 December as announced to Bursa Malaysia Securities Berhad on 22 April 2022. As such, there are no comparative figures available for the corresponding periods in the preceding year.



UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE FINANCIAL PERIOD ENDED 31 DECEMBER 2022⁽¹⁾

	UNAUDITED PERIOD ENDED 31 DEC 2022	UNAUDITED PERIOD ENDED 31 DEC 2021
CASH FLOWS FROM OPERATING ACTIVITIES	RM'000	RM'000
Loss before taxation	(21,549)	-
Adjustments for:	(==)0 :0)	
Depreciation of property, plant and equipment	2,158	-
Gain on disposal of property, plant and equipment	(22)	-
Gain on disposal of quoted investment	(1,500)	
Depreciation of right-of-use assets	1,682	-
Interest expense	407	-
Interest income	(464)	-
Property, plant and equipment written off	174	
Net written down on inventories	17,511	-
Reversal of impairment loss on other receivables	(5,406)	-
Reversal of impairment loss on trade receivables	(1,325)	-
Fair value loss on investment in quoted shares	12,800	-
Unrealised gain on foreign exchange	(92)	-
Share of loss of equity accounted associate	47	-
Operating profit before working capital changes	4,421	-
Decrease in inventories	(12,880)	-
Increase in trade and other receivables	2,243	-
Decrease in trade and other payables	(571)	-
CASH USED IN OPERATIONS	(6,787)	-
Income tax paid	(874)	-
Interest paid	(407)	-
Interest received	464	-
NET CASH USED IN OPERATING ACTIVITIES	(7,604)	-
CASH FLOWS FROM INVESTING ACTIVITIES		
Acquisition of property, plant and equipment	(26,008)	-
Acquisition of investment in quoted shares	(36,003)	-
Acquisition of right-of-use asset	(1,639)	-
Proceeds from disposal of right-of-use asset	25	-
NET CASH USED IN INVESTING ACTIVITIES	(63,625)	-
CASH FLOWS FROM FINANCING ACTIVITIES		
Drawdown of bankers' acceptances	1,130	-
Drawdown of term loans	1,825	-
Drawdown of finance leases	599	
Proceeds from issuance of ordinary shares via ESOS scheme	3,338	-
Proceeds from issuance of ordinary shares via private placement	11,258	
Repayment of lease liabilities	(971)	-
NET CASH GENERATED FROM FINANCING ACTIVITIES	17,179	-
NET DECREASE IN CASH AND CASH EQUIVALENTS	(54,050)	-
EFFECTS OF FOREIGN EXCHANGE RATE CHANGES ON THE BALANCE		
OF CASH HELD IN FOREIGN CURRENCIES	96	-
CASH AND CASH EQUIVALENTS AT 1 OCTOBER 2021	80,662	-
CASH AND CASH EQUIVALENTS AT 31 DECEMBER 2022	26,708	-
Cash and cash equivalents at end of the financial period comprise the following:		
Cash and bank balances	14,708	-
Fixed deposit with a licensed bank	12,000	-
	26,708	-

Note:-

(1) The basis of preparation of the Unaudited Condensed Consolidated Statements of Cash Flows is detailed in Note A1 and should be read in conjunction with the audited financial statements for the FPE 30 September 2021 and the accompanying explanatory notes attached to this interim financial report.

(2) The financial year end of the Company and the Group has changed from 30 September to 31 December as announced to Bursa Malaysia Securities Berhad on 22 April 2022. As such, there are no comparative figures available for the corresponding periods in the preceding year.



A. EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARDS ("MFRS") 134: INTERIM FINANCIAL REPORTING

A1. Basis of preparation

The interim financial report of LKL International Berhad ("LKL International" or "the Company") and its subsidiaries ("the Group") is unaudited and has been prepared in accordance with the requirements of MFRS 134 - Interim Financial Reporting issued by the Malaysian Accounting Standard Board ("MASB"), Paragraph 9.22 and Appendix 9B of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad ("Bursa Securities").

The interim financial report should be read in conjunction with the audited financial statements for the financial period ended 30 September 2021 ("FPE 2021"). These explanatory notes attached to the interim financial report provide explanation of events and transactions that are significant for the understanding of the changes in the financial position and performance of the Group since the FPE 2021.

Change in Financial Year End

As announced on 22 April 2022, the Company had changed its financial year end from 30 September to 31 December. As a result, the next annual audited financial statements of the Group shall be made up from 1 October 2021 to 31 December 2022 covering a period of 15 months and subsequently, the financial year of the Company shall end on 31 December.

A2. Changes in accounting policies

The Group has adopted those standards and interpretations (including the consequential amendments, if any) that have become effective on 1 January 2021 and such adoptions do not have material impact on the financial position and performance of the Group.

The Group has not applied in advance the following accounting standards and/or interpretations (including the consequential amendments, if any) that have been issued by the MASB but are not yet effective for this interim financial report: -

MFRSs and/or IC Interpretations (Including The Consequential Amendments)	Effective Date
Annual Improvements to MFRS Standards 2018 – 2020	1 January 2022
Amendments to MFRS 3: Reference to the Conceptual Framework	1 January 2022
Amendments to MFRS 116: Property, Plant and Equipment – Proceeds before Intended	
Use	1 January 2022
Amendments to MFRS 137: Onerous Contracts – Cost of Fulfilling a Contract	1 January 2022
MFRS 17 Insurance Contracts	1 January 2023
Amendments to MFRS 17: Insurance Contracts	1 January 2023
Amendments to MFRS 17: Insurance Contracts – Initial Application of MFRS 17 and MFRS 9	1 January 2023
Amendments to MFRS 101: Classification of Liabilities as Current or Non-current	1 January 2023
Amendments to MFRS 101: Definition of Accounting Estimates	1 January 2023
Amendments to MFRS 108: Disclosure of accounting policies	1 January 2023
Amendments to MFRS 112: Income Tax – Deferred Tax related to Assets and Liabilities	
arising from a Single Transaction.	1 January 2023
Amendments to MFRS 16: Lease Liability in a Sale and Leaseback	1 January 2024
Amendments to MFRS 101: Non-current Liabilities with Covenants	1 January 2024
Amendments to MFRS 10 and MFRS 128: Sales or Contribution of Assets between an	
Investor and its Associate or Joint Venture	Deferred

The adoption of the above accounting standards and/or interpretations (including the consequential amendments, if any) is expected to have no material impact on the interim financial report of the Group upon its initial application.



A. EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARDS ("MFRS") 134: INTERIM FINANCIAL REPORTING (CONT'D)

A3. Auditors' report on preceding audited financial statements

The preceding year's audited financial statements of the Group were not subject to any qualification.

A4. Seasonal or cyclical factors

The Group's business operations were not materially affected by seasonal or cyclical factors during the current financial quarter under review.

A5. Unusual items affecting assets, liabilities, equity, net income or cash flows

There were no material unusual items affecting assets, liabilities, equity, net income or cash flows of the Group during the current financial quarter and current period-to-date under review except as disclosed in the unaudited financial statements.

A6. Material changes in estimates

There were no changes in estimates that have had a material effect in the current financial quarter under review.

A7. Debts and equity securities

There was no other issuance, cancellation, repurchase, resale and repayment of debt and equity securities during the current financial quarter under review.

A8. Dividend paid

There was no dividend paid during the current financial quarter under review.



A. EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARDS ("MFRS") 134: INTERIM FINANCIAL REPORTING (CONT'D)

A9. Segmental information

(a) Analysis of revenue by product categories

	UNAUDITED INDIVIDUAL QUARTER			UNAUDITED CUMULATIVE PERIOD				
	31 DEC	2022	31 DEC 20	021	31 DEC	2022	31 DEC 2021	
	RM'000	%	RM'000	%	RM'000	%	RM'000	%
Manufacturing:								
Medical/healthcare								
beds	3,822	22.33	-	-	12,917	12.61	-	-
Medical peripherals								
and accessories	5,518	32.24	-	-	26,003	25.37	-	-
	9,340	54.57	-	-	38,920	37.98	-	-
Trading:			-	-			-	-
Medical peripherals								
and accessories	7,590	44.35	-	-	62,623	61.11	-	-
Medical devices	107	0.63	-	-	605	0.59	-	-
	7,697	44.98	-	-	63,228	61.70	-	-
Retail:								
Healthcare and								
Pharmaceuticals	77	0.45	-	-	328	0.32	-	-
Total revenue	17,114	100.00	_	-	102,476	100.00		-

(b) Analysis of revenue by geographical areas

	UNAUDITED			UNAUDITED				
	I	NDIVIDUA	L QUARTER		CUMULATIVE PERIOD			
	31 DEC	2022	31 DEC 20	021	31 DEC	2022	31 DEC 2021	
	RM'000	%	RM'000	%	RM'000	%	RM'000	%
Local:								
Malaysia	14,581	85.20	-	-	93,805	91.54	-	-
Export:								
Africa	1,778	10.39	-	-	2,536	2.47	-	-
Asia - other than								
Malaysia	229	1.34	-	-	4,899	4.78	-	-
Europe	282	1.65	-	-	654	0.64	-	-
Middle East	17	0.10	-	-	355	0.35	-	-
Central America	227	1.32	-	-	227	0.22	-	-
	2,533	14.80	-	-	8,671	8.46	-	-
Total revenue	17,114	100.00	-	-	102,476	100.00	-	-

A10. Valuation of property, plant and equipment

There was no valuation of the property, plant and equipment for the current financial quarter under review.



Α. EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARDS ("MFRS") 134: INTERIM FINANCIAL REPORTING (CONT'D)

A11. Material events subsequent to the end of the current financial quarter

On 22 February 2023, the Board of Directors of the Company had announced that that its wholly-owned subsidiary, LKL Advance Metaltech Sdn. Bhd. had on 21 February 2023 entered into a Sale and Purchase Agreement ("SPA") with Lembaga Kumpulan Wang Simpanan Pekerja ("KWSP") or also known as Employees Provident Fund Board, for the proposed acquisition of all that piece of leasehold land measuring approximately 2,301 square metres in area held under Pajakan Negeri 12257, Lot 934, Bandar Damansara, Daerah Petaling, Negeri Selangor together with a 12-storey commercial office block with a 5-storey car park containing 130 car park bays known as Bangunan KWSP Damansara Fairway erected thereon bearing the postal address of No. 6A, Persiaran Tropicana, Tropicana, 47410 Petaling Jaya, Selangor Darul Ehsan (collectively referred to as "the Property") for a total cash consideration of RM24,000,000.00 only ("Proposed Acquisition").

Save for the above, there were no other material events subsequent to the end of the current financial quarter that have not been reflected in this interim financial report.

A12. Changes in composition of the Group

There were no material changes in the composition of the Group for the current financial guarter under review.

A13. Contingent assets or contingent liabilities

The Group has no other contingent assets and contingent liabilities as at the date of this report except for the following:

(i) Contingent liabilities

	UNAUDITED AS AT 31 DEC 2022 RM'000	AUDITED AS AT 30 SEP 2021 RM'000
Bank guarantees given by financial institution to third parties	300	243
Capital commitments		
	UNAUDITED AS AT 31 DEC 2022 RM'000	AUDITED AS AT 30 SEP 2021 RM'000
Approved and contracted for:		
Purchase of property, plant and equipment	2,077	12,129

A15. **Related party transactions**

A14.

During the current financial quarter, the Board of Directors is of the opinion that there were no material related party transactions which would have a significant impact on the financial position and business of the Group.



B. ADDITIONAL INFORMATION REQUIRED BY THE LISTING REQUIREMENTS OF BURSA SECURITIES

B1. Review of performance of 15-month ended 31 December 2022

The financial year end of the Company and the Group has changed from 30 September to 31 December as announced to Bursa Malaysia Securities Berhad on 22 April 2022. As such, there are no comparative figures available for the corresponding periods in the preceding year.

The Group's performance for the 15-month ended 31 December 2022 is as tabled below:

	UNAUDITED
	CUMULATIVE PERIOD
	ENDED 31 DECEMBER
	2022
	RM'000
Revenue	102,476
Gross profit	14,935
Loss Before Tax	
("LBT")	(21,549)

The Group posted revenue of RM102.476 million for the current financial period ended 31 December 2022. The group revenue was mainly contributed by trading segment of RM63.228 million on the back of sales of test kits totaling RM45.464 million. The manufacturing of medical beds, peripherals and accessories segment contributed RM38.920 million or 37.98% of group revenue and the retail segment contributed RM0.328 million of the group revenue for the current financial period.

Geographically, the local market was the largest revenue contributor at RM93.805 million or 91.54% of the group revenue. Export sales contributed the remaining RM8.671 million or 8.46% of the group revenue for the current financial period.

The Group reported a gross profit of RM14.935 million and gross profit margin of 14.57% for the current financial period mainly due to a lower gross profit margin recorded in the trading sales of test kits and loss in the gross profit margin in the trading sales of glove.

Consequently, coupled with the impacts of the written down of glove inventories of RM16.045 million and the fair value loss on investment in quoted shares of RM12.800 million, the Group posted a LBT of RM21.549 million for the current financial period.

B2. Comparison with preceding quarter's results

	UNAUDITED CURRENT QUARTER ENDED 31 DECEMBER 2022 RM'000	UNAUDITED PRECEDING QUARTER ENDED 30 SEPTEMBER 2022 RM'000
Revenue	17,114	10,087
Gross profit (Loss)/Profit Before Tax ("LBT")/("PBT")	1,486(21,848)	2,850



B2. Comparison with preceding quarter's results (Cont'd)

The Group's revenue for the current financial quarter under review increased by 69.66% or RM7.027 million to RM17.114 million, from RM10.087 million in the preceding financial quarter, mainly due to higher trading sales of medical peripherals & accessories such as Nitrile Gloves.

Segmentally, the manufacturing segment constituted RM9.340 million of Group revenue in the current financial quarter, an increase of 25.71% or RM1.910 million from RM7.430 million in the preceding financial quarter. The trading segment registered revenue of RM7.697 million, increased 197.99% or RM5.114 million from RM2.583 million in the preceding financial quarter, was attributed from higher sales of medical peripherals and accessories. Meanwhile, the retail segment made up RM0.077 million in revenue, raised 8.45% or RM0.006 million from RM0.071 million in the preceding financial quarter.

The Group posted a lower gross profit of RM1.486 million and a lower gross profit margin of 8.68% in the current financial quarter as compared with RM2.850 million and 28.25% in the preceding financial quarter mainly due to the written down of glove inventories for the trading segment.

Consequently, the Group recorded a LBT of RM21.848 million as compared with a PBT of RM0.254 million in the preceding financial quarter, mainly due to fair value loss on investment in quoted shares.

B3. Prospects

In view of the improvement in personal and public health awareness after the outbreak of COVID-19 pandemic, the Group is cautiously optimistic that robust healthcare expenditure levels will complement its future prospects. The higher demand is driven by a growing ageing population in Malaysia and regional countries, improving disposable income levels, medical advancements, and increasing public health awareness.

However, we continue to note market uncertainties and challenges attributed to rising inflation and supply chain disruptions globally, further exacerbated by the prolonged Russia-Ukraine war as well as lockdowns in China. As a result, the Group faces higher cost for key raw materials in the manufacturing segment, such as steel sheets, electrical components, and hydraulic pumps, which resulted in higher cost of sales for the business, thereby affecting our gross profit margin.

To mitigate the rising costs, the Group will continue to cushion the impact through prudent cost optimisation and tight management of internal efficiencies. Apart from efficiency improvement initiatives, the Group also seeks to expand and enhance our product portfolio to cater for a wider range of needs as well as higher-value segments.

To capture more growth opportunities, the Group is expanding our domestic sales and marketing efforts and increasing participation in overseas trade exhibitions and roadshows amid international border restrictions ease further.

The Group's forward strategy involves reinforcing our position as a reliable, one-stop solutions provider to the medical and healthcare industry. To achieve this, we strive to offer a more comprehensive range of products in our manufacturing and trading segments, as well as explore synergistic businesses.

The Group will prudently continue to focus on its existing revenue generation business and enhance its operating efficiency by streamlining manufacturing processes to improve production capacity. In respect of the pharmacy business, the Group will cautiously assess the demand from time to time to capture opportunities in the business-to-consumer segment.



B4. Tax expense

	UNAUDITED INDIVIDUAL QUARTER ENDED 31 DEC 2022 RM'000	UNAUDITED CUMULATIVE PERIOD ENDED 31 DEC 2022 RM'000
Current tax expense Overprovision in prior financial period	(223)	- (956) (956)

The provision for tax payable was made for profitable subsidiaries and certain expenses of the group were disallowed for tax purposes.

B5. Variance of actual profit from profit forecast and profit guarantee

The Group has not issued any profit forecast or profit guarantee in any form of public documentation and announcement during the current financial quarter under review.

B6. Status of corporate proposals

Save as disclosed below, there were no other corporate proposals announced but not completed as at the date of this report.

- (i) On 17 June 2022, TA Securities had announced on behalf of the Board that LKL International proposed to undertake the following:
 - (a) proposed consolidation of every 10 ordinary shares in LKL ("LKL Shares" or "Shares") into 1 LKL Share ("Consolidated Share") ("Proposed Share Consolidation");
 - (b) proposed diversification of the principal activities of LKL and its subsidiaries ("LKL Group") to include the operation of pharmacies including retailing of pharmaceutical, healthcare and personal care products ("Proposed Diversification");
 - (c) proposed renounceable rights issue of up to 291,480,180 LKL Shares ("Rights Shares") together with up to 194,320,120 free detachable warrants in LKL ("Warrants") on the basis of 3 Rights Shares together with 2 free Warrants for every 1 Consolidated Share held by the entitled shareholders of LKL on an entitlement date to be determined ("Proposed Rights Issue with Warrants"); and
 - (d) proposed establishment of a share issuance scheme of up to 30% of the total number of issued Shares of LKL (excluding treasury shares, if any) to the eligible directors and eligible employees of LKL Group ("Proposed SIS").

On 18 August 2022, TA Securities had announced the approval had been granted for the above by Bursa Securities.

On 20 September 2022, The Board of Directors of LKL International Berhad had announced all proposed exercise mentioned above were duly passed by the shareholders of the Company by voting at the EGM of the Company.

On 17 October 2022, TA Securities had announced that the Share Consolidation has been completed following the listing and quotation of 97,160,054 Consolidated Shares on the ACE Market of Bursa Securities.



B6. Status of corporate proposals (Cont'd)

On 30 January 2023, TA Securities had announced that Bursa Securities had, vide its letter dated 30 January 2023, resolved to grant the Company an extension of time until 17 May 2023 to implement and complete the Rights Issue with Warrants and thereafter implement the SIS.

ON 10 February 2023, TA Securities had announced that the Company has resolved to fix the issue price of the Rights Shares at RM0.17 per Rights Share ("Issue Price") and the exercise price of the Warrants at RM0.17 per Warrant ("Exercise Price") and the last date and time for acceptance, excess application and payment is 14 March 2023 at 5.00 p.m.

On 24 February 2023, TA Securities had announced that the abridged prospectus of the Company in relation to the Rights Issue with Warrants, together with the notice of provisional allotments and rights subscription form have been duly registered by Bursa Securities and lodged with the Registrar of Companies.

B7. Utilisation of proceeds from the Private Placements

(i) Pursuant to the 1st Private Placement, the details of the issuance of Placement Shares as at the date of this report are as follows:

Tranches	Issuance Date	No. of Shares	Issue Price (RM)	Total Proceeds (RM)
Tranche 1	26 November 2020	44,540,000	0.8600	38,304,400
Tranche 2	6 January 2021	12,570,000	0.8300	10,433,100
Tranche 3	18 January 2021	10,000,000	0.8466	8,466,000
Tranche 4	10 March 2021	1,000,000	0.4030	403,000
Tranche 5	15 March 2021	1,000,000	0.3840	384,000
Tranche 6	17 March 2021	3,500,000	0.3750	1,312,500
Tranche 7	9 April 2021	13,150,000	0.2690	3,537,350
		85,760,000		62,840,350

The status of utilisation of proceeds as at the date of this report is as follows:

	Purposes	Proceeds raised RM'000	Actual utilisation RM'000	Deviation RM'000	Unutilised proceeds RM'000	Estimated timeframe for utilisation
(a)	Capital expenditure and expansion	26,500	12,610	-	13,890	Within 24 months
(b)	Future investments or projects	6,000	6,000	-	-	Within 24 months
(c)	Repayment of bank borrowings	5,561	5,561	-	-	Within 6 months
(d)	Working capital	23,779	23,896	(117) ⁽¹⁾	-	Within 12 months
(e)	Estimated expenses in relation to the Proposals	1,000	883	117 ⁽¹⁾	-	Within 1 month
	Total	62,840	48,950	-	13,890	

Note:-

(1) In view that the actual listing expenses were less than estimated, the surplus has been re-allocated for working capital purposes.



B7. Utilisation of proceeds from the Private Placements (Cont'd)

(ii) Pursuant to the 2nd Private Placement, the details of the issuance of Placement Shares as at the date of this report are as follows:

Tranches	Issuance Date	No. of Shares	Issue Price (RM)	Total Proceeds (RM)
Tranche 1	3 September 2021	144,000,000	0.2050	29,520,000
Tranche 2	3 September 2021	26,033,200	0.2050	5,336,806
Tranche 3	15 November 2021	7,490,000	0.0930	696,570
		177,523,200		35,553,376

The status of utilisation of proceeds as at the date of this report is as follows:

	Purposes	Proceeds raised RM'000	Actual utilisation RM'000	Deviation RM'000	Unutilised proceeds RM'000	Estimated timeframe for utilisation
(a)	Trading of rubber gloves and PPE	32,953	30,029	(86) ⁽¹⁾	3,010	Within 24 months
(b)	Setting up new storage facilities	2,000	252	-	1,748	Within 24 months
(c)	Estimated expenses in relation to the Proposals	600	514	86 (1)	-	Within 1 month
	Total	35,553	30,795	-	4,758	

Note:-

(1) In view that the actual listing expenses were less than estimated, the surplus has been re-allocated for trading of rubber gloves and PPE.

B8. Group's borrowings and debt securities

The Group's borrowings as at 31 December 2022 were as follows:

	UNAUDITED AS AT 31 DEC 2022 RM'000	AUDITED AS AT 30 SEP 2021 RM'000
Current:		
Bankers' acceptance	1,368	238
Lease liabilities	1,201	1,213
Term loans	402	422
	2,971	1,873
Non-current:		
Lease liabilities	1,214	1,471
Term loans	6,734	4,889
	7,948	6,360
Total borrowings:		
Bankers' acceptance	1,368	238
Lease liabilities	2,415	2,684
Term loans	7,136	5,311
	10,919	8,233

All the borrowings were secured and denominated in Ringgit Malaysia.



B9. Material litigation

Save as disclosed below, there is no litigation or arbitration which has a material effect on the financial position of the Group and the Board of Directors is not aware of any proceedings pending or threatened, or of any fact likely to give rise to any proceedings as at the date of this report.

(i) LKL Advance Metaltech Sdn. Bhd. vs Crecom Burj Gloves Sdn. Bhd. (WA-24NCC(ARB)-37-12/2020)

On 16 December 2020, LKL Advance Metaltech Sdn. Bhd. had through its solicitors, Messrs. Chong + Kheng Hoe, filed an Originating Summons in the High Court in Kuala Lumpur bearing registration number: WA-24NCC(ARB)-37-12/2020 ("OS") against Crecom Burj Gloves Sdn. Bhd. ("Defendant").

The High Court had on 5 March 2021 granted a Mareva injunction to freeze the Defendant's asset up to the amount of RM12,542,783 after hearing all parties involved.

On 9 April 2021, the Defendant filed an affidavit to declare and list out all the necessary details of its assets and current locations of the same. The Defendant had filed an appeal bearing appeal no. W-02(NCC)(A)-719-04/2021 to the Court of Appeal, Putrajaya to appeal against the injunction granted by the High Court in Kuala Lumpur to the Plaintiff. However, the Defendant has withdrawn its appeal No. W-02(NCC)(A)-719-04/2021 at the Court of Appeal on 9 September 2021.

In line with the OS, the Plaintiff had also filed a Notice of Arbitration dated 11 January 2021 ("Arbitration") against the Defendant. The Plaintiff claims against the Defendant for breach of the Purchase Agreement dated 2 October 2020 which was entered into by both parties for the purchase of gloves from the Defendant. In the Arbitration, the Plaintiff is seeking from the Defendant the sum of RM12,542,783.60, general damages, interest, costs and any further relief that the arbitral tribunal thinks fit and just.

The Defendant filed a Response to the Arbitration dated 16 February 2021 counterclaiming for the sum of RM20,374,500.00 for the purported balance amount due to the Defendant. The Arbitration is pending appointment of arbitrator by the director of Asian International Arbitration Centre. There was no progress in the case as at the date of this report.

(ii) LKL Advance Metaltech Sdn. Bhd. vs Crecom Burj Gloves Sdn. Bhd. and 6 others (WA-22NCC-331-07/2021)

On 26 July 2021, LKLAM had through its solicitors, Messrs Chong + Kheng Hoe, filed a Writ and Statement of Claim in the High Court in Kuala Lumpur bearing suit number: WA-22NCC-331-07/2021 ("Suit") against the Crecom Burj Gloves Sdn Bhd, Crecom Burj Group Sdn Bhd, Datin Roslinda Binti Jaafar, Khairil Anuar Bin A. Rahman, Nurul Ashikin Binti Muhammad Muhiyuddin, Chew Seng Ker and Nurul Balqis Binti Khairul Anuar ("Defendant")

The Plaintiff is claiming against Defendants for the return of RM12,540,757.20 being payment made by the Plaintiff for the purchase of gloves from Crecom Burj Group Sdn Bhd pursuant to the Purchase Agreement dated 2 October 2020. The Suit is fixed for trial on 27 Feb to 3 March 2023.

On 23 August 2022, the second Defendant, Crecom Burj Group Sdn Bhd has been wound up by the Kuala Lumpur High Court. LKLAM has filed a post-winding up suit no. WA-28PW-620-12/2022 to obtain leave from the Kuala Lumpur High Court to continue the proceeding against the second Defendant, Crecom Burj Group Sdn Bhd in suit WA-22NCC-331-07/2021. The hearing of this application has been fixed on 16 February 2023.

On 29 September 2022, the first Defendant, Crecom Burj Gloves Sdn Bhd has been wound up by the Shah Alam High Court. LKLAM has filed a post-winding up suit no. BA-28PW-314-12/2022 to obtain leave from the Shah Alam High Court to continue the proceeding against the first Defendant, Crecom Burj Gloves Sdn Bhd in suit WA-22NCC-331-07/2021. The hearing of this application has been fixed on 6 March 2023.



B9. Material litigation (Cont'd)

Save as disclosed below, there is no litigation or arbitration which has a material effect on the financial position of the Group and the Board of Directors is not aware of any proceedings pending or threatened, or of any fact likely to give rise to any proceedings as at the date of this report (Cont'd)

(ii) LKL Advance Metaltech Sdn. Bhd. vs Crecom Burj Gloves Sdn. Bhd. and 6 others (WA-22NCC-331-07/2021) (Cont'd)

Pending the leave hearing and also pending appointment of solicitors for Crecom Burj Group Sdn Bhd and Crecome Burj Gloves Sdn Bhd, the court as vacated the upcoming trial dates on 27 February 2023 to 3 March 2023. The new trial dates are 20, 21, 23 and 24 May 2024.

(iii) LKL Advance Metaltech Sdn. Bhd. vs Genesis Gateway Sdn. Bhd. (WA-28NCC-800-11/2021)

On 8 November 2021, LKLAM ("Petitioner") has had through its solicitors, Messrs. Chong + Kheng Hoe, presented a Winding Up Petition at the Kuala Lumpur High Court registered under Companies (Winding-Up) No. WA-28NCC-800-11/2021 against Genesis Gateway Sdn Bhd ("Respondent") for the sum of RM13,311,960.96, indebted by the Respondent to the Petitioner wherein the Petitioner is seeking inter alia for the Respondent to be wound up by the Court and the incidental reliefs related thereto. The Court has also appointed a liquidator of the Respondent and Petitioner has filed their proof of debt to the liquidator on 31 October 2022.

(iv) LKL International Berhad vs The Edge Communications Sdn. Bhd. (WA-23NCvC-50-05/2021)

On 25 May 2021, the Company had through its solicitors, Messrs. Wong Kian Kheong, filed a Writ and Statement of Claim in the High Court in Kuala Lumpur against The Edge Communications Sdn. Bhd. ("The Edge"). The suit was initiated against The Edge for the article published at pages 62 to 64 of "The Edge Malaysia" on 12 April 2021 entitled "Hidden hands behind penny stock surge under scrutiny" ("Article"), of which the Company alleged that certain words in the Article were defamatory of LKL International Berhad.

The Company is seeking from The Edge, amongst others, damages and an injunction to restrain The Edge whether by itself, its agents or servants or otherwise from publishing or causing to be published the same or similar words defamatory of the LKL International.

On 19 August 2021, the Edge has filed a striking out application to strike out the Company's claim, and the High Court has on 17 May 2022 dismissed The Edge's striking application with costs in the cause. The Court has further fixed the Suit for trial on 15 to 17 January 2024.

B10. Dividend proposed

There was no dividend proposed for the current financial quarter under review.



B11. Loss per share ("LPS")

The basic LPS for the current financial quarter and financial period-to-date are computed as follows:

	UNAUDITED INDIVIDUAL QUARTER ENDED 31 DECEMBER 2022	UNAUDITED CUMULATIVE PERIOD ENDED 31 DECEMBER 2022
Net loss attributable to ordinary equity holders of the Company (RM'000)	(21,625)	(20,488)
Weighted average number of ordinary shares in issue ('000)	971,601	925,416
Basic LPS (sen)	(2.23)	(2.21)

B12. Notes to the Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Income

LBT is arrived at after charging/(crediting):

	UNAUD		UNAUDITED CUMULATIVE PERIOD ENDED		
	INDIVIDUAL QUA				
	31 DEC 2022 RM'000	31 DEC 2021 RM'000	31 DEC 2022 RM'000	31 DEC 2021 RM'000	
Depreciation of property, plant and					
equipment	442	-	2,158	-	
Gain on disposal of property, plant and					
equipment	-	-	(22)	-	
Gain on disposal of quoted investments	-	-	(1,500)	-	
Property, plant and equipment written off	174	-	174	-	
Depreciation of right-of-use assets	343	-	1,682	-	
Interest expense	118	-	407	-	
Interest income	(87)	-	(464)	-	
Net written down on inventories	15,942	-	17,511	-	
Reversal of impairment loss on other					
receivables	(3,559)	-	(5,406)	-	
Reversal of impairment loss on trade					
receivables	(160)	-	(1,325)	-	
Fair value loss on investment in quoted shares	12,800	-	12,800	-	
Realised loss on foreign exchange	55	-	21	-	
Unrealised loss/(gain) on foreign exchange	53	-	(92)		

Other disclosure items pursuant to Appendix 9B Note 16 of the ACE Market Listing Requirements of Bursa Securities are not applicable.

B13. Authorisation for Issue

The interim financial report was authorised for issue by the Board of Directors on 28 February 2023.